Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 12, 2011, Pages 434-440

  Mach, Tomasz H ^a   Cieśla, Andrzej ^a   Warunek, Wioleta ^a   Janas Skulina, Urszula ^a   Cibor, Dorota ^a   Owczarek, Danuta ^a   Ciećko Michalska, Irena ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Chronic hepatitis; HCV genotype 1b; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLAND; TREATMENT RESPONSE;

EID: 84855271662     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1109     Document Type: Article

References (38)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5: 558-567. (Pubitemid 41196755)
2. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2011; 55: 245-264.
3. Cieśla A, Mach T. [Chronic viral hepatitis - current epidemiological, clinical and therapeutic challenge]. Przegl Gastroenterol. 2007; 2: 69-73. Polish.
4. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004; 24 (Suppl 2): 3-8. (Pubitemid 39180700)
5. Czepiel J, Biesiada G, Mach T. Viral hepatitis C. Pol Arch Med Wewn. 2008; 118: 734-740.
6. Fried MW, Hadziyannis MD. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis. 2004; 24 (Suppl 2): 47-54. (Pubitemid 39180706)
7. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat. 2005; 12: 223-235. (Pubitemid 40638030)
8. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55: 1350-1359. (Pubitemid 44277369)
9. Hofmann WP, Zeuzem S: A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011; 8: 257-264.
10. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis. 2004; 24 (Suppl 2): 25-31. (Pubitemid 39180703)
11. Ge D, Fellay J, Thompson AJ, Simon JS, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401.
12. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41: 1100-1104.
13. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41: 1105-1109.
14. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798-801.
15. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol. 2010; 45: 903-910.
16. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin 28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010; 139: 120-129.
17. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol. 2011; 106: 38-45.
18. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008; 47: 1260-1269.
19. de Segadas-Soares JA, Villela-Nogueira CA, Perez RM, et al. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis C patients treated with peginterferon-alpha2b and ribavirin? J Clin Gastroenterol. 2009; 43: 362-366.
20. Juszczyk J, Beniowski M, Berak H, et al. Effectiveness of combined treatment with pegylated interferon α-2a and ribavirin in chronic hepatitis C - study phase summary. Med Sci Monit. 2004; 10 (Suppl 1): 5-11.
21. Juszczyk J, Baka-Ćwierz B, Beniowski M, et al. [Pegylatd interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report). Przegl Epidemiol. 2005, 59: 651-660. Polish.
22. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010; 138: 116-122.
23. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010; 138: 108-115.
24. Awad T, Thorlund K, Hauser G, et al. Peginterferon alfa-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010; 51: 1176-1184.
25. Mach T, Cieśla A, Sanak M, et al. The importance of IL28B polymorphism in response to pegylated interferon alfa and ribavirin in chronic hepatitis caused by HCV genotype 1b. Przegl Gastroenterol. 2011. [In press].
26. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995; 19: 1409-1417.
27. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001; 358: 958-965. (Pubitemid 32913521)
28. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975-982.
29. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346-355.
30. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361: 580-593.
31. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology. 2011; 53: 336-345.
32. Zeuzem S, Alberti A, Rosenberg W, et al.: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. Aliment Pharmacol Ther. 2006; 24: 1133-1149. (Pubitemid 44427502)
33. Shiffman ML, Diago M, Tran A, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol. 2006; 4: 645-652.
34. Prati D, Shiffman ML, Diago M, et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol. 2006; 44: 679-685.
35. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004; 127: 1724-1732. (Pubitemid 39575851)
36. Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol. 2011; 26 Suppl 1: 96-101.
37. Skowroński M, Zozulińska-Ziółkiewicz D, Juszczyk J, et al. C-reactive protein and chronic hepatitis C virus infection in diabetic patients. Pol Arch Med Wewn. 2010; 120: 491-496.
38. Saryusz-Wolska M, Szymańska-Garbacz E, Jabłkowski M: Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. Pol Arch Med Wewn, 2011; 121: 61-66.